Page 2 - Arch Pathol Lab News Today

/PRNewswire/ -- Bio-Techne (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical...

Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca's trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy Daiichi

Integrating nanophotonic technologies into biosensor systems has seen increased interest as advancements in nanotechnology are made. Read more in this article.

Daiichi Sankyo and AstraZeneca's ENHERTU also improved median overall survival by more than 6 months vs. chemotherapy in all patients evaluated in DESTINY-Breast04 ENHERTU met the primary

WILMINGTON, Del.--(BUSINESS WIRE)--Jun 5, 2022--

Antwerp, Belgium, May 25th 2022 (PRWEB) May 27, 2022 -- Pathomation, a leading pioneer in universal digital pathology software solutions, is excited to

AstraZeneca and Daiichi Sankyo’s Enhertu has been granted Breakthrough Therapy Designation in the US for the treatment of adult patients with unresectable or...

Histology is the microscopic study of cells and tissues and plays a central role in disease diagnosis. Through the identification of characteristic features in tissue structures, it is possible to diagnose cancers and many other diseases by comparing changes in the cellular structure between healthy and diseased tissues.

07.03.2022 - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) - (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“AstraZeneca”) ...

Investegate announcements from AstraZeneca PLC, Enhertu improves PFS and OS in HER2-low BC